News
»
Vivacelle Bio, Inc. Announces FDA Clearance to Enroll Patients into a Phase IIa Clinical Trial of VBI-S for Elevation of Blood Pressure in Subjects Who Have Shock Due to Sepsis
Vivacelle Bio, Inc. Announces FDA Clearance to Enroll Patients into a Phase IIa Clinical Trial of VBI-S for Elevation of Blood Pressure in Subjects Who Have Shock Due to Sepsis
Vivacelle Bio, Inc. announces that the US Food and Drug Administration (FDA) has granted Dr. Cuthbert Simpkins, MD its Founder and Chief Innovation Officer, an Investigational New Drug (IND) clearance to proceed with a phase IIa clinical trial of the safety and efficacy of VBI-S. Vivacelle Bio, Inc. provided support for the investigational new drug application to the U.S. Food & Drug Administration for a phase IIa clinical trial of VBI-S.
Latest News
(BPRW) Kappa Alpha Psi Fraternity, Inc. announces new $2 million fundraising commitment for St. Jude Children’s Research Hospital
(BPRW) The Congressional Black Caucus Foundation Partners with Paramount Pictures on the Release of the new “Bob Marley: One Love” Film to Provide Social Justice Scholarships
(BPRW) Americans Willing to Pay More to Eliminate the Racial Wealth Gap, Creating a New Opportunity for Black Business Owners
(BPRW) ALLBLK RELEASES TRAILER FOR FIFTH SEASON OF DOUBLE CROSS, PREMIERING JANUARY 18